Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
Background:
People who have had a traumatic brain injury (TBI) often have trouble sleeping. TBI may also alter hormones, which can cause poor sleep. Researchers believe that a form of growth hormone releasing hormone (GHRH) might improve sleep in service members and veterans who have had a TBI.
Objective:
To see if GHRH can improve sleep in people who have had a TBI.
Eligibility:
Active duty
Study InterventionsTesamorelin, PlaceboPrimary EndpointsChange in NREM time following tesamorelin administration compared to placeboStudy Period2016-10-06 → 2017-03-08 Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity. This study is a single arm prospective study of tesamorelin therapy of patients with HIV lipodystrophy. Subjects will do body composition testing, adipose tissue biopsy, metabolic rate m
Study InterventionsTesamorelinPrimary EndpointsChange in Hepatic Lipid ContentStudy Period2018-02-07 → 2025-04-30 Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in d
Study InterventionsTesamorelin, Placebo, ExercisePrimary EndpointsChange in Repeated Chair Stand TimeStudy Period2025-07-07 → 2028-12-01 Egrifta Replacement and Sleep Disordered Breathing
Sleep-disordered breathing is characterized primarily by partial or total upper airway obstruction during sleep. The most common form of sleep-disordered breathing is obstructive sleep apnea (OSA) due to recurrent collapse of the upper airway with the onset of sleep state. The major risk factors associated with the development of sleep apnea are obesity and male sex. The investigators have also fo
Study InterventionsTesamorelin (Egrifta)Primary EndpointsChanges in Sleep Apnea Severity; Changes in Sleep Apnea SeverityStudy Period2012-05 Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesize that treatment with tesamorelin will result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves. Patients with upper extremity nerve injuries will be randomly assigned to receive
Study InterventionsTesamorelin 2 Milligrams (MG)Primary Endpoints3-point chuck pinch testStudy Period2018-06-01 → 2027-12 Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
The primary objective of the study is to determine the PK (tesamorelin) and PD (IGF-1) profiles of tesamorelin after a single 2 mg subcutaneous administration and after repeated administration once daily for 14 consecutive days. Secondary objectives include the evaluation of the safety and tolerability of tesamorelin following multiple subcutaneous injections.
Study InterventionsTesamorelinPrimary EndpointsArea under the Plasma Concentration versus Time Curve (AUC) of Tesamorelin.; Peak Plasma Concentration (Cmax) of Tesamorelin.Study Period2008-05 → 2008-07 TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
Study InterventionsTesamorelin, Placebo for TesamorelinPrimary EndpointsChanges From Baseline in Fasting Blood Glucose at Week 52; Changes From Baseline in 2 h Oral Glucose Tolerance Test (OGTT) at Week 52Study Period2007-08 → 2008-10 Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
Obesity is strongly associated with risk of cardiovascular disease (CVD). Data increasingly suggest that visceral adipose tissue (VAT) accumulation -- or increased abdominal fat -- is particularly deleterious to cardiovascular health, but further study is needed to test this idea. Increased abdominal fat may also be associated with lower secretion of a hormone called growth hormone (GH), which hel
Study InterventionsTesamorelin, PlaceboPrimary Endpointsaortic "target to background ratio" (Aortic TBR)Study Period2014-01 → 2014-01 Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular disease. Abdominal obesity, in particular, is also associated with low levels of growth hormone, a hormone that affects rate of growth and the way the body uses energy. Gro
Study InterventionsGrowth hormone releasing hormone (GHRH) 1-44, PlaceboPrimary EndpointsChange in Visceral Adipose Tissue VolumeStudy Period2008-07 → 2012-01 Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.
Study InterventionsTesamorelinPrimary EndpointsChange in Neurocognitive PerformanceStudy Period2017-02-15 → 2023-10-15